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How Are We Going to Live With Alzheimer's Disease?
Abstract
Alzheimer’s disease confronts us with an ethical challenge: How do we live with dignity and quality of life
in the face of progressive disability and, ultimately, death? Patients’ cognitive and decision-making
impairments often make them unable to answer this question, and when professionals who provide
services for older adults fail to recognize and accommodate these impairments, patients suffer. Patients
and their caregivers need a health care system that fosters caregiving so that each will live with dignity
and well-being. Another way to answer this question is to discover treatments that prevent disabling
cognitive impairments, but this strategy will require expanding the Alzheimer’s label to include people who
do not have dementia or who are even cognitively normal. Controversies are likely to occur over how best
to describe the Alzheimer’s problem, measure the value of early diagnosis and treatment, and live with a
brain at risk.
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How Are We Going To Live With Alzheimer’s Disease?
Abstract
Alzheimer’s disease confronts us with an ethical challenge:
How do we live with dignity and quality of life in the face of
progressive disability and, ultimately, death? Patients’
cognitive and decision-making impairments often make them unable
to answer this question, and when professionals who provide
services for older adults fail to recognize and accommodate
these impairments, patients suffer. Patients and their
caregivers need a health care system that fosters caregiving so
that each will live with dignity and well-being. Another way to
answer this question is to discover treatments that prevent
disabling cognitive impairments, but this strategy will require
expanding the Alzheimer’s label to include people who do not
have dementia, or who are even cognitively normal. Controversies
are likely to occur over how best to describe the Alzheimer’s
problem, measure the value of early diagnosis and treatment, and
live with a brain at risk.

Rising prevalence, increasing costs, and persistent failure
to discover effective pharmacologic treatments have made
Alzheimer’s disease a national problem that evokes disaster
images such as “silver tsunami” and “epidemic.” The United

States is responding. In 2011 President Obama signed the
National Alzheimer’s Project Act into law. Commonly called NAPA,
it has led to an integrated national plan.(1)
As policy makers develop and implement this plan, they
should recognize that Alzheimer’s disease confronts patients
with an ethical challenge--“How do I live with dignity and
quality of life in the face of progressive disability and,
ultimately, death?” A system of laws, ethics, and social norms
grants each of us the freedom to answer this question and to
respect each other’s autonomy to do the same, but patients with
Alzheimer’s disease face challenges in their ability to
participate in this system.
Over time, patients not only develop disabilities
performing daily tasks, such as taking their medications safely,
but also develop impairments in deciding how best to manage
these problems, a phenomena that reflects how patients often
underestimate or even do not recognize their disabilities.(2)
They also develop impairments in their decision-making
abilities.(2-4) The failure to recognize and accommodate these
complex disabilities can cause a patient to suffer harms; such
as losses of dignity and respect, abuse, neglect, and
exploitation. Our national plan for Alzheimer’s disease
therefore requires an ethical response.

First, early in the disease, patients vary in whether they
retain the ability to make day-to-day decisions about matters
such as money management and living arrangements. Professionals
who provide services for older adults, especially in long-term
care, and the legal, banking, and financial services industries
need methods to assess and monitor their clients’ decisionmaking abilities, and, when they detect impairments, take
appropriate action. Secondly, as cognitive and functional
impairments worsen, patients need other people, typically a
family member or friend, to care for them. As these caregivers
witness the person “die twice,” first in mind and then a few
years later in body, they make day-to-day and often ethically
charged decisions for the patient as they themselves experience
notable morbidity, especially depression.(5) Patients and their
caregivers need a health care system that fosters caregiving so
that each will live with dignity and well-being.
Another response to prevent the harms of losses of dignity
and respect, as well as abuse, neglect, and exploitation, is to
prevent Alzheimer’s disease, and one of goals of the US national
Alzheimer’s plan (released in 2012) is that by 2025, the United
States will discover a treatment that prevents, halts, or even
reverses the onset of disabling cognitive impairments.
Partnerships between the NIH, academia, and the pharmaceutical

industry have launched large-scale studies to reach this
ambitious goal.(6,7) Discovering an effective treatment requires
a diagnosis prior to dementia or even mild cognitive
impairments, an approach that will need to accommodate a new
understanding of the label “Alzheimer’s disease:” It does not
necessarily equate to having dementia or even any symptoms of
cognitive impairment.
This understanding will present new ethical and policy
challenges. As the number of people with Alzheimer’s disease
expands along a diverse continuum that includes people at risk
of disability to those who are extremely disabled, controversies
are likely to occur over how best to describe the Alzheimer’s
disease problem, how big it is, how to demonstrate the value of
early diagnosis and treatment, and how to live with a brain at
risk.
Facilitating Decision-Making
Medicine, psychology, and the law have made substantial
progress developing and translating a conceptual model of
decision-making capacity. The model requires that for a given
decision, the clinician assess the person’s decision-making
abilities. This assessment informs the clinician’s judgment
whether the person is able to provide informed consent, or
instead, needs assistance, or even someone else, to provide

consent.(8,9) Studies show that patients with very mild to
moderate stage Alzheimer’s disease have substantial variability
in their decision-making abilities. They are able to express a
choice, meaning they can state what they do or do not want, such
as declining to attend an adult day-care program, but they often
have clinically significant impairments in their abilities to
understand relevant facts and appreciate how an intervention
such as adult care will help them.(4,10) Comparing patients’
capacity to make different decisions shows that they may retain
the capacity to make one kind of decision, such as appointing a
surrogate, but lack the capacity to make a more complex
decision, such as whether to join a research study that involves
a neurosurgical intervention.(11)
These findings explain why most very mild to moderate stage
patients either make a decision with someone else or someone
else makes decisions for them,(12) and that neither the
diagnostic label of Alzheimer’s disease dementia nor the scores
on cognitive and functional measures from very mild to moderate
stage disease can substitute for an assessment of decisionmaking capacity.
Medical decisions are, of course, just one kind of
important and often ethically charged decision patients make.
They also make decisions about long-term care, and legal,

banking, and other financial matters. Although the professionals
in these fields may not know whether their clients have
Alzheimer’s disease, cognitive changes that impact everyday
decision-making are common among older adults.(13) It would be
very beneficial if these professionals had the skills to assess
older adults’ decisional abilities. The more they possess these
skills, the better they can decide whether an older adult’s
decision is a decision to be respected, or instead, signals a
problem in need of monitoring or even intervention.
These skills are especially important for professionals
working in the financial services and banking industries. They
are essentially on the front lines of screening for cognitive
impairment because declines in financial decision-making
capacity are among the earliest functional changes seen in
people with Alzheimer’s disease.(14) These professionals need
professional standards and regulatory guidance that set out
their obligations to identify people with impaired financial
decision-making capacity, training in how to do this, and, how
to address people with impaired capacity.(15,16)
However, it might be argued that non-medical professionals
should not assess older adults’ decision-making abilities
because such assessments are medical matters. Certainly, in high
stakes or contested decisions such as a major asset transfer or

whether to move from one home to another, medical consultation
may well be essential, but as a matter of daily practice,
physicians and the courts cannot be brought into adjudicating
whether a patient has capacity to make each and every daily
decision.
Older adults should at least expect that professionals who
work with them are skilled in effectively communicating with
them and their caregivers. The ability to assess capacity is
among the skills of a good teacher. When, for example, an adult
protective services caseworker asks an older adult who has had
several emergency department visits for medication errors, “Do
you think that using a weekly pill box for your medications
could benefit you?” the caseworker is assessing the client’s
ability to appreciate the benefits of an intervention, which is
one of the decision-making abilities physicians use to judge
capacity. The caseworker is also engaging in good communication
with someone whose problem managing medications suggests the
presence of a cognitive impairment.(4) Caseworkers and discharge
planners may find an instrument such as the Assessment of
Capacity for Everyday Decisionmaking useful to assess and
document a person’s decision-making abilities.(3,4)
Enduring The Unendurable

This section’s title is taken from one of Arthur Kleinman’s
essays about his wife’s decline and ultimate death from
Alzheimer’s disease.(17,18) Kleinman, a psychiatrist and
anthropologist, has studied the ways patients make sense of
disease and the role clinicians have in eliciting patients’
illness experiences.(19) Turning these skills to understanding
his experiences caring for his spouse, he arrived at insights of
substantial ethical and policy importance.
Kleinman came to see how the person with the disease and
the person who cares for them essentially exchange roles. “She
is happy much of the time. It is me, the caregiver, who, more
often, is sad and despairing.”(17) Studies reinforce this.
Patients consistently rate their quality of life and functional
abilities better than caregivers rate patients’ quality of life
and functional abilities,(2,20) and caregivers experience
notable symptoms of depression.(5) In short, not only patients
but their caregivers have an illness experience.
Kleinman’s solution to endure this gradual exchange of
roles is caregiving, a deeply interpersonal practice that
resonates with matters of living, self, and dignity.(17) Because
caregiving is an indelible part of what it means to be human, it
is therefore among the foundations of our common moral
experience. People such as Kleinman use this experience to make

day-to-day and often ethically charged decisions. Unfortunately,
medicine and the health care system have largely neglected this
foundation; for example, caregivers do not have ready access to
education and training. In the care of people with Alzheimer’s
disease, this is a notable shortcoming because patients often
underestimate or even entirely deny that they have functional
problems, and, as a result, may decline care. In such a
situation, the caregiver is the ethically appropriate means to
provide patient-centered care. What follows are initiatives that
policy makers can take to foster caregiving.
A 2012 NAPA-commissioned review of interventions to support
caregivers found multiple randomized and controlled trials and
translational studies that show psychosocial and environmental
interventions and training can foster caregiving that, in turn,
benefits both patients and their caregivers.(21) The Resources
for Enhancing Alzheimer’s Caregiver Health (REACH) studies, for
example, show that intervention strategies such as education,
problem solving, and telephone support groups can improve
caregiver mood and well-being and reduce patient morbidity.(22)
Unfortunately, interventions such as REACH are not part of the
routine care of a person with Alzheimer’s disease in the same
manner as prescriptions for mildly effective symptomatic
medications. A prescription for caregiver training should be as

available as, for example, nutritional consultation and
education are part of the routine care of a patient with
diabetes.
Other interventions that can foster caregiving include
redesigning the electronic medical record (EMR).(23) The default
design records the care of an individual patient who, via a
“patient portal,” remotely accesses it to check results and to
communicate with providers. For patients who need caregivers,
this design is insufficient. Caregivers need access to this
exchange of patient information.. Medicare requirements for how
clinicians should use the EMR need to include a record of the
patient’s caregivers and their roles, and allow them access to
the patient’s portal.
As patients decline, they have increasing needs for both
palliative and hospice care, but delivering hospice care to them
faces structural problems. Predicting that a patient with
dementia has a six-months or less life expectancy and is
therefore eligible for the Medicare hospice benefit is
challenging.(24) Patients often live beyond this life
expectancy, putting them at great risk of being discharged from
hospice care. A sensible reform would be to allow patients with
severe stage dementia to enroll and remain in hospice as long as
it fits their goals of care, rather than their life expectancy.

“Enduring the unendurable” has been about the ethics of
living with progressive and disabling cognitive impairments;
that is, living with dementia. For much of the 20th century,
Alzheimer’s disease and dementia were tightly linked
concepts.(25) Now, at the beginning of the 21st century, that
link is beginning to fracture. In its place is a new concept of
Alzheimer’s disease, that it is a continuum of decline beginning
when a person is cognitively normal. This presents novel
challenges to living with Alzheimer’s disease.
Preparing For The ‘Brain At Risk’
Our approaches to Alzheimer’s disease diagnostics and
treatment as well as our understandings of its prevalence,
costs, and personal and family burdens have relied on diagnostic
criteria issued in 1984.(26) Often called the “McKhann
criteria,” shorthand for their lead author Guy McKhann, the
criteria define Alzheimer’s disease as a clinical diagnosis
explained by a characteristic pathology. The clinical diagnosis
describes a person whose history of cognitive and functional
impairments follows a stereotypical pattern. The pathology that
explains this dementia is commonly called “plaque and tangle
Alzheimer’s disease,” because between the neurons are dense
deposits of a protein called amyloid (amyloid plaques) and

within the deceased neurons, there are tangles of fibrils (tau
tangles).
By the close of the 20th century, researchers argued that
numerous inconsistencies between what the 1984 criteria
suggested researchers should observe versus what they actually
did observe required new criteria. Their most provocative
observations came from studies performing serial measures of
older adults’ cognition, function, brain structure and function,
and tissues such as spinal fluid; and post-mortem brain
autopsy.(27) First, Alzheimer’s plaque and tangle pathology can
be found post-mortem in older adults who were cognitively
normal. Second, older adults with dementia typically have not
only Alzheimer’s pathology, but other pathologies as well, most
notably vascular disease. Third, distinct measures of brain
pathophysiology, commonly called “biomarkers,” seem to predict
which older adults start out cognitively normal, but, over time,
develop disabling cognitive impairments.
In 2011, three National Institute on Aging-Alzheimer’s
Association workgroups revised the criteria for dementia caused
by Alzheimer’s disease and added two non-dementia stages to the
disease: a mild cognitive impairment stage characterized by
measurable impairments in cognition without dementia and a stage
defined entirely by biomarkers and their connection to future

cognitive impairment, called “preclinical Alzheimer’s
disease.”(28-30) The International Working Group for New
Research Criteria for the Diagnosis of Alzheimer’s Disease has
also proposed similar criteria for “asymptomatic at risk for
Alzheimer’s disease.”(31) Their lingua franca are the biomarkers
and genes that might identify who will progress from cognitive
normality or mild cognitive impairment to Alzheimer’s disease
dementia.
“Preclinical” or “asymptomatic at risk for Alzheimer’s
disease” are not concepts ready for clinical practice, but they
are eligibility criteria for ongoing studies whose results will
standardize biomarkers, distinguish normal from abnormal
biomarker levels, and identify people in need of treatment.
McKhann, some twenty-seven years after the publication of the
criteria that informally bear his name, explains a view echoed
by his fellow NIA workgroup members, that the most important of
these studies are clinical trials. “The ultimate goal of these
recommendations is to realign the clinical and research
diagnostic approach with potential therapies…. Waiting for the
appearance of dementia would be tantamount to physicians trying
to prevent heart disease in only those who have had a myocardial
infarction.”(32)

The National Institutes of Health (NIH), in cooperation
with pharmaceutical industry partners, has committed at least
$100 million to four clinical trials whose goal is to identify
cognitively normal people with either a genetic or biomarkerdefined risk of cognitive decline in order to intervene with a
pharmacological intervention that will slow this decline. The
Anti-Amyloid in Asymptomatic Alzheimer’s Study (the A4 Study),
for example, a joint NIH- and Eli Lilly–sponsored randomized and
controlled trial, is enrolling cognitively normal adults ages
65–85 who have elevated amyloid as detected on a PET scan to
test whether three-and-a-half years of treatment with an antiamyloid drug slows the rate of cognitive decline.(7) Similar
studies are ongoing or are soon to start in cognitively normal
people who are at heightened genetic risk of developing
Alzheimer’s disease dementia. If the studies are successful,
they will begin to redefine Alzheimer’s disease into a
biomarker-based diagnosis that is largely independent of the
clinical expression of the disease.
The conceptual model of these studies comes from clinical
trials for other diseases of aging whose results established
tight links among a biomarker, a drug that targets the
biomarker, and an outcome measuring the chance of a future
clinical event.(33) Clinical trials have transformed diseases

such as heart disease and osteoporosis from clinical to
biomarker-based diagnoses, as, for example, the biomarker of
cholesterol engenders statin treatment to reduce the risk of
heart attack. Diagnosing and treating Alzheimer’s disease in a
preclinical stage has tremendous appeal to both an individual’s
health and the public health, but this also presents ethical and
policy challenges.
A common feature of chronic diseases of aging is that they
unfold slowly and insidiously, and then, in a thunderclap, the
patient is sick. Stroke, heart attack, hip fracture, and acute
congestive heart failure are dramatic events that share common
features. They are easily measured and therefore easily
quantified. These events are also readily understood by
researchers, clinicians, patients, and policy makers. These
features are of substantial advantage to translating into
clinical practice the results of trials in diabetes,
cardiovascular disease, and osteoporosis.
Alzheimer’s disease prevention trials do not measure these
kinds of events. Their primary endpoint is the slope of decline
in a measure of cognition. This measure is a composite of
several cognitive tests, most of which are not used in clinical
practice. This endpoint presents a pressing problem: how to
translate it into clinical practice and treatment guidelines?

This problem will have substantial importance and urgency
because the number of people who are “biomarker positive” and
therefore potentially eligible for a prevention therapy could be
in the millions. For example, among adults age sixty-five and
older who are cognitively normal, about one-third are amyloid
positive on PET scans.(28)
Addressing this problem will require approaches that use
the results of clinical trials and longitudinal cohort studies
to create prediction models, also called algorithms, that
demonstrate the kinds of patients who will benefit from
interventions.(34) What data will be used, and how the models
will be designed, interpreted, and updated are matters of
interrelated scientific, ethical, and public policy importance.
Unlike the Food and Drug Administration–regulated drug approval
process, treatment algorithms and guidelines are typically
developed by professional societies. They are more likely to
experience the conflicts of interest that arise when
professional, private, and scientific interests compete.(35)
As one or more combinations of biomarkers defines the
disease, the prevalence of people with Alzheimer’s disease will
increase, but as it increases, it will begin to encompass a
diverse spectrum of patients, ranging from those who have
dementia, to persons who are cognitively normal but “biomarker

positive.” These different kinds of people with the disease will
undermine the ability of having one prevalence number to express
the magnitude of the problem and therefore its costs.
As people are labeled with biomarker-defined Alzheimer’s
disease, they will have to live with and make sense of a label
that renegotiates the boundaries between a healthy brain versus
a brain at risk for a disease Americans fear even more than
cancer.(36,37) People in the preclinical stage of the disease
may well be working and want to purchase long-term care
insurance, so legal reforms and professional initiatives will be
needed to minimize discrimination in employment and
insurability. Over time, despite treatment, some patients may
develop symptoms and signs of cognitive impairment. This
reiterates the importance of training professionals in law,
banking, and finance on how to assess decision-making abilities
and, if they detect impairments, the actions they should take.
Conclusion
One afternoon at the Memory Center where I care for
patients, a caregiver interrupted his narrative of his wife’s
decline and insisted, “I have Alzheimer’s disease!” In a sense,
he’s right. As researchers unleash Alzheimer’s disease from the
category of people with dementia to a continuum of cognitive
decline, each of us is even more likely to have it. Short of a

cure, prevention will delay but not eliminate cognitive
impairment. As this impairment slowly degrades a patient’s
autonomy, the disease will inevitably engage others and these
caregivers will suffer as well. Whether as patients or as
caregivers, we all have Alzheimer’s disease. The question we
must engage is how should we live with it?
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